RankAlpha logo
Back to Rankings

PCVX

VaxcyteD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
PCVX vs peer average
26/100
PCVX vs. peer average (D vs. B)
Grade spread
A 3 · B 2 · C 2 · D 3
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

MRK is the first available peer comparator.

Merck is the clearest direct operating comparator because VAX-31 is being positioned against CAPVAXIVE in adult pneumococcal vaccination, making competitive immunogenicity, serotype breadth and safety central to any eventual commercial case. [#10-K-2026-02-24]

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerMRKMerck
PCVX
Vaxcyte
MRK
Merck
Grade
D
B
Momentum
15
62
Value
41
65
Sentiment
88
56
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Defensive
Constructive
Open Side-by-Side ComparisonCompare all

Grade position vs MRK

PCVX / MRK
Grade Position
Below peers
PCVX vs. peer average (D vs. B)
26/100
Momentum
15
MRK
Value
41
MRK
Sentiment
88
PCVX

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs PCVX
1
MRK
MRK
B
80/100
-2
2
NUVL
NUVL
C
60/100
-1
3
PFE
PFE
C
60/100
-1
4
ALKS
Alkermes plc Common
A
100/100
-3
5
RGEN
Repligen Corp Common
D
40/100
Even
MRK is the first peer returned for this comparison set.